Wednesday, July 8, 2026

pharma · Pancreatic Adenocarcinoma · Cancer · ACTU

Actuate Therapeutics

Actuate Therapeutics is a pharma organization headquartered in Fort Worth, USA. It trades on NYSE under ticker ACTU. Primary therapeutic focus areas include Pancreatic Adenocarcinoma, Cancer, Refractory Hematologic Malig

1751 River Run, Suite 400, Fort Worth, Texas 76107, US HQ
2015 Founded
16 Employees
Public company Type
ACTU · NYSE Ticker
Company details
Status
Public
HQ
1751 River Run, Suite 400, Fort Worth, Texas 76107, US
Founded
2015
Employees
16
Programs
12
Drugs
11
Patents
7
Clinical program

9-ING-41

Phase 2 · small molecule · Cancer

9-ING-41 for Cancer is a Phase 2 program (small_molecule) at ACTUATE THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).

← All ACTUATE THERAPEUTICS, INC. projects Phase 2 small molecule active

Internal code 1801

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
ACTUATE THERAPEUTICS, INC.
Phase
Phase 2
Modality
small_molecule
Indication
Cancer
Status
active
Trials
1

Clinical trials